About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

359,057 studies
in
219 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 01/18/2021.
This website is for US healthcare professionals

Log In to Bolder Science

or

Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 01/18/2021.

Cohabitation Patterns and Incidence of Known and Suspected Sexually Transmitted Diseases

Clinicaltrials.gov identifier NCT03941158

Recruitment Status Completed

First Posted May 7, 2019

Last update posted May 7, 2019

Study Description

Brief summary:

The number of infectious agents associated with risks of malignant hematologic diseases is non-negligible and include both viruses and bacteria. The various organisms affect cancer risk either directly by transforming susceptible cells, through chronic antigenic stimulation or by hampering immune function in other ways conducive of cancer development. Suspicion of an infectious cancer origin may arise because of clustering with other conditions (e.g. immune deficiency), specific environments or settings (e.g. geographic locales) or with exposures (e.g. blood transfusions). In this context, relatively few studies have addressed clustering of diseases among spouses to generate hypotheses about the relative contributions of environmental and genetic factors to the risk of individual cancer types. As a prelude to such an exercise aiming specifically at malignant hematologic diseases, we will test an algorithm characterising cohabitation patterns in the Danish population to assess the risk of sexually transmitted diseases in analyses of register data. Such information will also be relevant to current guidelines for blood donor deferral policies. Specifically, because of the so-called precautionary principle all blood donations are extensively tested for infectious agents and transfusion of blood now carries an extremely low risk of transmission of HIV, hepatitis B and C. The residual risk of HIV transmission in Denmark is estimated to 1:10,000,000 transfusions. However, several deferral criteria have existed for years without studies to prove their relevance. Aim: To compare the incidence of both known and suspected sexually transmitted diseases between different cohabitation patterns in the Danish population. Perspectives: The study results can be used to leverage changes in deferral rules in the Danish blood banks to accommodate strong wishes from stakeholders to avoid the perceived discrimination of various minorities. The study can thus have important ethical and political consequences.

  • Condition or Disease:Cohabitation Patterns
    Sexually Transmitted Diseases
  • Intervention/Treatment:
  • Phase: N/A
Detailed Description

N/A

Study Design
  • Study Type: Observational
  • Actual Enrollment: 5000000 participants
  • Observational Model: Cohort
  • Time Perspective: Retrospective
  • Official Title: Cohabitation Patterns and Incidence of Known and Suspected Sexually Transmitted Diseases
  • Actual Study Start Date: April 1968
  • Actual Primary Completion Date: December 2018
  • Actual Study Completion Date: December 2018
Outcome Measures
  • Primary Outcome Measures: 1. Sexually transmitted diseases [ Time Frame: 1977 - 2018 ]
    The diseases will be identified by using the Danish National Patient Register (NPR). Diagnostic information is based on the International Classification of Diseases, Eight and Tenth Revision (ICD-8 and ICD-10).
  • 2. HIV, syphilis, and gonorrhea [ Time Frame: 2005 - 2018 ]
    HIV, syphilis, and gonorrhea will be identified by registration in the Mandatory disease notification system administrated by Statens Serums Institut (SSI), Denmark.
Eligibility Criteria
  • Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
  • Sexes Eligible for Study: All
  • Accepts Healthy Volunteers:
  • Sampling Method: Probability Sample
  • Study Population: In Denmark, every citizen is registered with a unique identification number in the Civil Registration System. Adult persons (18 years or older) who resided in Denmark for any period between 1 April 1968 and primo 2018 will be identified and linked to national health registers by using the unique identification number. Different living arrangements can be defined by using an address-based algorithm to identify each citizen's complete day-by-day cohabitation or marital status history.
Criteria

Inclusion Criteria:

- All citizens in Denmark

Exclusion Criteria:

- Institutionalized individuals

Contacts and Locations
Contacts
Locations
Sponsors and Collaborators

Aarhus University Hospital

Statens Serum Institut

Investigators

Principal Investigator: Christian Erikstrup, Professor, Chief Physician Aarhus University Hospital

More Information
  • Responsible Party: Aarhus University Hospital
  • ClinicalTrials.gov Identifier: NCT03941158 History of Changes
  • Other Study ID Numbers: 2015-57-0102
  • First Posted: May 7, 2019 Key Record Dates
  • Last Update Posted: May 7, 2019
  • Last Verified: May 2019
  • Studies a U.S. FDA-regulated Drug Product: No
  • Studies a U.S. FDA-regulated Device Product: No
  • Additional relevant MeSH terms: Sexually Transmitted Diseases